Research Article

Low-Dose Dexamethasone Therapy from Infancy of Virilizing Congenital Adrenal Hyperplasia

Scott A. Rivkees and Kerry Stephenson

Department of Pediatrics, Yale Child Health Research Center, Yale University School of Medicine, New Haven, CT 06520, USA

Correspondence should be addressed to Scott A. Rivkees, scott.rivkees@yale.edu

Received 19 September 2009; Accepted 27 October 2009

Recommended by Jeffrey Gruen

Objective. To assess the growth and control of adrenal androgen secretion in children with virilizing congenital adrenal hyperplasia (CAH) treated with dexamethasone. Method. We examined doses used, control of adrenal androgen secretion, and growth and skeletal maturation of 8 children with CAH treated with dexamethasone beginning in infancy. Results. 3 boys and 5 girls with classical CAH (17-hydroxyprogesterone at diagnosis >20,000 ng/dL) were treated with dexamethasone beginning at diagnosis (<10 days of age). Patients were also treated with fludrocortisone and sodium chloride. The average initial medication dose was 0.1 mg (0.28 ± 0.015 mg/m²); all doses were given in the morning using a dosing syringe to administer a 0.1 mg/mL elixir. The children were treated for 6.5 ± 2.0 years over which time the change in bone age to chronological age ratio (ΔBA/ΔCA) was 0.9 ± 0.06. Most recent height Z-scores were +0.5 ± 0.2, and body mass index (BMI) scores were 18 ± 2. Late afternoon levels of 17-hydroxyprogesterone, androstenedione, and testosterone were 780 ± 238 ng/dL (23.4 ± 7 nmol/L), 42 ± 10 ng/dL (1.4 ± 0.3 nmol/L), and 11.5 ± 3 ng/dL; (0.4 ± 0.1 nmol/L), respectively. Conclusions. These observations show that low doses of dexamethasone can be used to effectively treat CAH beginning in infancy.

1. Introduction

Congenital adrenal hyperplasia (CAH) is characterized by the inability to produce adequate amounts of glucocorticoids and mineralocorticoids, and reciprocal excessive production of androgens [1–3]. Untreated, CAH can result in adrenal crisis attendant by circulatory collapse and hypoglycemia [1–3]. Excessive androgen production can result in a prenatal and postnatal virilization [1–3]. As result, treatment of CAH is essential for the well being of the child.

Mainstays of CAH therapy include treatment with glucocorticoids and mineralocorticoids. To date, the majority of patients with CAH have been treated with hydrocortisone, which is a compound with a short circulating half-life [4, 5]. The use of longer acting glucocorticoids including prednisone and dexamethasone has also been reported [6–8]. Caution, though, has been recommended in using prednisone and dexamethasone due to the high potency of these compounds [4, 5].

When applied in the treatment of CAH, the relative potency of prednisone to hydrocortisone of 4 to 5 to 1 has been used by some groups [6]. The potency of dexamethasone relative to hydrocortisone has been regarded to be approximately 30 to 1 [9]. However, these are anti-inflammatory, not anti-adrenal potencies [10]. Rather, prednisone is approximately 15 times more potent than hydrocortisone [8] and dexamethasone is 80 to 100 fold more potent [7] than hydrocortisone in suppressing adrenal androgen production.

The use of dexamethasone in the treatment of CAH was introduced in 1971 [11]. Subsequent studies have shown that dexamethasone can control excessive adrenal androgen production used once a day, making this form of treatment convenient for families [7].

In 2000 we reported our experience using dexamethasone for the treatment of 26 boys and girls with CAH [7]. The average dose used to treat these patients was 0.27 mg/m²/day, with doses given in the morning [7]. On this regimen, there
Table 1: Circulating adrenal hormone levels for infants treated with dexamethasone for CAH.

| Hormone            | Normal prepubertal levels* | Infants with CAH        | Fold increase |
|--------------------|----------------------------|-------------------------|---------------|
| 17-OHP (ng/dL)     | 40 (3–100)                 | 780 ± 238               | 20-fold       |
|                    | 1.4 (0.09–3)               | 23.4 ± 7                |               |
| Androstenedione (ng/dL) | 25 (8–50)                 | 42 ± 10                 | 1.7-fold      |
|                    | 1 (0.32–2)                 | 1.4 ± 0.3               |               |
| Testosterone (ng/dL) | 5 (3–10)                   | 11.5 ± 3                | 2.2-fold      |
|                    | 0.17 (0.1–0.3)             | 0.4 ± 0.1               |               |

*From Esoterix Laboratory Services, Inc.

was comparable maturation of linear and skeletal growth [7]. That population of children included individuals who had treatment onset at 2.8 years of age [7]. Those studies did not report our experience of dexamethasone used in infants treated from infancy onward. We now report the outcome of children with CAH treated with dexamethasone beginning at birth.

2. Methods

This analysis was approved by the Yale Human Investigation Committee. The medical records of all patients with a diagnosis of CAH were evaluated. Patients were included for analysis if they were treated continuously with dexamethasone from infancy onward.

Dexamethasone was administered at initial dose of 0.1 mg each morning. A 0.1 mg/mL elixir of generic dexamethasone was used. Doses were administered between 7:00 and 9:00 a.m. using a dosing syringe. When the patients were ill, parents were instructed to give a double dose in the morning, and the same double dose in the evening for the duration of illness plus one day.

Patients were evaluated clinically every three to four months at which time height, weight, and blood pressure were assessed. Laboratory tests were obtained between 3:00 and 5:00 p.m. for determination of circulating concentrations of 17-hydroxyprogesterone, androstenedione, testosterone, renin, and electrolytes. All hormonal determinations were performed at commercial diagnostic laboratories (Esoterix Life Sciences or Quest Laboratories). Every six months, after the age of one year, radiographs of the left hand and wrist were obtained for bone age determination using the Greulich and Pyle atlas [12]. Radiographs were interpreted by pediatric radiologists who were unaware of the clinical condition of the children.

Doses were increased when the 17-hydroxyprogesterone levels were above 1,000 ng/dL and the androstenedione and testosterone levels were more than 2-fold above normal. Doses were decreased when the 17-hydroxyprogesterone levels were less than 250 ng/dL and the androstenedione and testosterone levels were normal or below normal, or there was excessive weight gain assessed at home (>0.5 kg in 2 weeks). When dose adjustments were made, doses were generally changed by 10%. Laboratory testing was repeated 2 months after dose changes.

All data pertaining to height, weight, drug doses, and laboratory test results were extracted from medical records and were recorded in an Excel data spread sheet. Height and body mass index (BMI) Z scores were determined using United States National Center for Health Statistics (NCHS) reference charts. Data are presented as mean ± SEM.

3. Results

Three boys and five girls were identified as having CAH by newborn screening and treated with dexamethasone from birth. The average 17-hydroxyprogesterone levels were 58,400 ± 12,000 ng/dL at 48 hours of age. In all patients, the diagnosis of congenital adrenal hyperplasia was confirmed by repeat measurement of 17-hydroxyprogesterone levels and/or ACTH stimulation testing using standard criteria [13]. The average age at diagnosis and treatment onset was 8 ± 2 days.

Seven infants were diagnosed with 21-hydroxylase deficiency; one infant had 11-hydroxylase deficiency. The average Prader score of girls was 3.2 ± 0.3. The individual with 11-hydroxylase deficiency was Prader stage 4 at diagnosis. All patients were also treated with 0.1 mg of fludrocortisone once daily, plus 1.5 mL, three or four times a day, of 23% sodium chloride solution orally.

For the patients with 21-hydroxylase deficiency, average late-afternoon 17-hydroxyprogesterone levels were 780 ± 238 ng/dL (23.4 ± 7 nmol/L) (Table 1). Androstenedione levels were 42 ± 10 ng/dL (1.4 ± 0.3 nmol/L). Testosterone levels were 11.5 ± 3 ng/dL (0.4 ± 0.1 nmol/L). [Normal levels for prepubertal individuals: 17-hydroxyprogesterone 40 ng/dL, range 3 to 100; (1.4 nmol/L, range 0.09 to 3); androstenedione, 25 ng/dL, range of 8 to 50 (1 nmol/L, range 0.32 to 2); testosterone, 5 ng/dL, range of 3 to 10 (0.17 nmol/L; range 0.1 to 0.3)].

When the linear growth was evaluated, growth rate Z scores were 1.1 ± 0.1 (Table 2). At an average of 6.5 years of age, height Z scores were 0.5 ± 0.2 and the average body mass index (BMI) was 18.2 ± 1.5. The mean bone age was 5.1 ± 1.5 years, with a bone age to chronologic age ratio of 0.9 ± 0.6 years (Figure 1).

When begun on a dose of 0.1 mg of dexamethasone each morning, seven patients did not require a change in the dexamethasone dose until 1.5 years of age. In one child, the dexamethasone dose was reduced at six months of age,
These literature entrenched equivalencies are potent than hydrocortisone in suppressing adrenal androgen production, respectively. When prednisone and hydrocortisone are used at 5- and 30-fold potencies relative to hydrocortisone, children will be over treated, as reflected in a recent report detailing the use of prednisone during adolescence [9].

The average dose initially used for treating the infants with dexamethasone was 0.25 mg/m²/day. (In comparison, most infants treated with hydrocortisone during infancy are treated with 20 mg/m²/day [14–16].) As the infants became older, most remained on a dexamethasone dose within 30% of the dose started in infancy. Thus, at the end of the follow-up period, the average daily dose of dexamethasone was 0.18 mg/m²/day. For children treated with hydrocortisone for CAH, typical doses are 15–20 mg/m²/day [5]. Thus, compared with standard hydrocortisone doses, dexamethasone is 80–100 fold more potent than hydrocortisone.

On low doses of dexamethasone, linear growth was normal in all children. Body mass index scores were normal in all children, indicating that the children gained weight normally.

When circulatory androgen levels were assessed, they were measured at the end of the day. Testing was performed at this time, as over the years we assessed circulating hormone levels at different times of the day, and we found that late afternoon levels correlated best with dose adjustments that allowed us to optimize growth and normal weight gain. At late afternoon, circulating testosterone and androstenedione levels were close to, or 2-fold above the normal range. The 17-hydroxyprogesterone levels were 10- to 20-fold above normal.

Previous studies have evaluated long-term linear growth in individuals treated with the short-acting glucocorticoid hydrocortisone [16]. In general, these studies reveal final adult heights are 1 to 2 standard deviations below that expected [16]. In our previous studies of older children treated with dexamethasone for CAH, we observed final or projected final height standard deviations scores of 0.2 [7]. In the current study, the bone ages were slightly less than the chronological ages. Thus, based on growth and skeletal maturation parameters, the linear growth in dexamethasone-treated children appears normal. Long-term follow-up of these children will be needed to ascertain long-term outcomes more than one decade from now.

Although we show that dexamethasone can be used to effectively treat CAH, it is important to emphasize that dexamethasone is a very potent glucocorticoid and overtreatment can occur. To avoid overtreatment, it is imperative that the dilute elixir (0.1 mg/mL) be used, and the dose should be administered with a syringe. Although it is tempting to give the dose at night to suppress morning adrenal androgen production, nighttime dosing of dexamethasone is associated with overtreatment [17]. Thus, the morning is the favored time for administration. When dose changes are made, changes are by 10% to 20%, and we instruct families to monitor the child’s weight with a scale at home. If the weight

### Table 2: Clinical Characteristics of patients at end of observation period.

| Age (yrs)         | 6.5 ± 2 |
|-------------------|---------|
| Height Z score    | 0.3 ± 0.2 |
| Growth velocity Z score | 1.1 ± 0.1 |
| BMI               | 18.2 ± 1.5 |
| Bone age (yrs)    | 5.1 ± 1.5 |
| BA/CA             | 0.9 ± 0.6 |
| Dexamethasone dose| 0.18 ± 0.2 mg/m²/d |

**Figure 1:** Bone age (BA) versus chronological age (CA) in individual children treated with dexamethasone for CAH. Dashed line is the line of unity.
increases by 0.5 kg over two weeks, the dose is empirically reduced.

In summary, we show that treatment of virilizing CAH from infancy onward with low-dose dexamethasone is effective. Children treated with low doses of dexamethasone for CAH have normal linear growth, weight gain, and appropriate skeletal maturation. The convenience of once a day dosing, and the relatively few dose changes that are needed over the first several years of life contribute to a favorable regimen for the treatment of infants. Further studies involving larger numbers of children are indicated to assess the utility for this approach before it is broadly applied.

References

[1] P. W. Speiser, “Prenatal and neonatal diagnosis and treatment of congenital adrenal hyperplasia,” Hormone Research, vol. 68, supplement 5, pp. 90–92, 2007.

[2] F. G. Riepe and W. G. Sippell, “Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency,” Reviews in Endocrine and Metabolic Disorders, vol. 8, no. 4, pp. 349–363, 2007.

[3] I. A. Hughes, “Congenital adrenal hyperplasia: a lifelong disorder,” Hormone Research, vol. 68, supplement 5, pp. 84–89, 2007.

[4] P. E. Clayton, W. L. Miller, S. E. Oberfield, et al., “Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society,” Hormone Research, vol. 58, no. 4, pp. 188–195, 2002.

[5] P. E. Clayton, W. L. Miller, S. E. Oberfield, E. M. Ritten, W. G. Sippell, and P. W. Speiser, “Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology,” Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 9, pp. 4048–4053, 2002.

[6] W. Bonfig, S. Bechtold, H. Schmidt, D. Knorr, and H. P. Schwarz, “Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty,” Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 5, pp. 1635–1639, 2007.

[7] S. A. Rivkees and J. D. Crawford, “Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth,” Pediatrics, vol. 106, no. 4, pp. 767–773, 2000.

[8] Z. Punthakee, L. Legault, and C. Polychronakos, “Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency,” Journal of Pediatrics, vol. 143, no. 3, pp. 402–405, 2003.

[9] Physicians Desk Reference: Edward Barnhart; 1999.

[10] L. Wilkins, The Diagnosis and Treatment of Endocrine Disorders in Childhood, C.C. Thomas, Springfield, Ill, USA, 1950.

[11] A. Hayek, J. D. Crawford, and H. H. Bode, “Single dose dexamethasone in treatment of congenital adrenocortical hyperplasia,” Metabolism, vol. 20, no. 9, pp. 897–901, 1971.

[12] W. W. Greulich and S. I. Pyle, Radiographic Atlas of Skeletal Development of the Hands and Wrists, Stanford University Press, Chicago, Ill, USA, 1959.

[13] M. I. New and R. S. Newfield, “Congenital adrenal hyperplasia,” Current Therapy in Endocrinology and Metabolism, vol. 6, pp. 179–187, 1997.

[14] M. I. New, “Extensive clinical experience: nonclassical 21-hydroxylase deficiency,” Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 11, pp. 4205–4214, 2006.

[15] D. P. Merke and S. R. Bornstein, “Congenital adrenal hyperplasia,” The Lancet, vol. 365, no. 9477, pp. 2125–2136, 2005.

[16] E. A. Eugster, L. A. DiMeglio, J. C. Wright, G. R. Freidenberg, R. Seshadri, and O. H. Pescevitz, “Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis,” Journal of Pediatrics, vol. 138, no. 1, pp. 26–32, 2001.

[17] M. C. Young and I. A. Hughes, “Dexamethasone treatment for congenital adrenal hyperplasia,” Archives of Disease in Childhood, vol. 65, no. 3, pp. 312–314, 1990.